Ascendis Pharma A/S (ASND) stock
ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 7/30
$267.07+7.79 (+3.00%)
Close on Nov 12, 2026Market cap $16.55BP/E 21.7Yield –
Ascendis Pharma A/S operating margin
Operating margin is operating income as a percentage of revenue.
Ascendis Pharma A/S's operating margin for the twelve months ending Jun 30, 2026 was 25.4%. For fiscal 2025 it was -18.9%, against -76.7% the year before. The highest annual figure on record is -18.9% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -18.9% | +57.7 |
| FY2024 | Dec 31, 2024 | -76.7% | +94.1 |
| FY2023 | Dec 31, 2023 | -170.8% | +927.1 |
| FY2022 | Dec 31, 2022 | -1097.9% | +4710.7 |
| FY2021 | Dec 31, 2021 | -5808.6% | −1053.5 |
| FY2020 | Dec 31, 2020 | -4755.1% | −3060.0 |
| FY2019 | Dec 31, 2019 | -1695.1% | −232.5 |
| FY2018 | Dec 31, 2018 | -1462.6% | +5827.7 |
| FY2017 | Dec 31, 2017 | -7290.3% | −5707.1 |
| FY2016 | Dec 31, 2016 | -1583.2% | −1067.9 |
| FY2015 | Dec 31, 2015 | -515.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 65.0% | +98.5 |
| Q1 FY2026 | Mar 31, 2026 | 10.1% | +113.3 |
| Q4 FY2025 | Dec 31, 2025 | 4.0% | +3.8 |
| Q3 FY2025 | Sep 30, 2025 | 5.1% | +172.4 |
| Q2 FY2025 | Jun 30, 2025 | -33.5% | +336.7 |
| Q1 FY2025 | Mar 31, 2025 | -103.2% | −52.0 |
| Q4 FY2024 | Dec 31, 2024 | 0.2% | +26.8 |
| Q3 FY2024 | Sep 30, 2024 | -167.3% | +112.5 |
| Q2 FY2024 | Jun 30, 2024 | -370.2% | −73.0 |
| Q1 FY2024 | Mar 31, 2024 | -51.2% | +376.5 |
| Q4 FY2023 | Dec 31, 2023 | -26.6% | +617.1 |
| Q3 FY2023 | Sep 30, 2023 | -279.8% | +665.3 |
| Q2 FY2023 | Jun 30, 2023 | -297.2% | +2006.3 |
| Q1 FY2023 | Mar 31, 2023 | -427.8% | +1447.3 |
| Q4 FY2022 | Dec 31, 2022 | -643.7% | +1655.3 |
| Q3 FY2022 | Sep 30, 2022 | -945.1% | +7764.0 |
| Q2 FY2022 | Jun 30, 2022 | -2303.5% | +9206.2 |
| Q1 FY2022 | Mar 31, 2022 | -1875.1% | +14834.1 |
| Q4 FY2021 | Dec 31, 2021 | -2299.0% | +15578.2 |
| Q3 FY2021 | Sep 30, 2021 | -8709.1% | −5850.0 |
| Q2 FY2021 | Jun 30, 2021 | -11509.7% | −5733.4 |
| Q1 FY2021 | Mar 31, 2021 | -16709.1% | −13419.0 |
| Q4 FY2020 | Dec 31, 2020 | -17877.2% | −15290.5 |
| Q3 FY2020 | Sep 30, 2020 | -2859.1% | −450.9 |
| Q2 FY2020 | Jun 30, 2020 | -5776.3% | −4170.1 |
| Q1 FY2020 | Mar 31, 2020 | -3290.1% | −2250.6 |
| Q4 FY2019 | Dec 31, 2019 | -2586.7% | −2245.7 |
| Q3 FY2019 | Sep 30, 2019 | -2408.2% | +189026.8 |
| Q2 FY2019 | Jun 30, 2019 | -1606.2% | +250854.9 |
| Q1 FY2019 | Mar 31, 2019 | -1039.5% | +124581.9 |
| Q4 FY2018 | Dec 31, 2018 | -341.0% | +11030.5 |
| Q3 FY2018 | Sep 30, 2018 | -191435.0% | −184183.2 |
| Q2 FY2018 | Jun 30, 2018 | -252461.1% | −246905.5 |
| Q1 FY2018 | Mar 31, 2018 | -125621.4% | −119287.8 |
| Q4 FY2017 | Dec 31, 2017 | -11371.4% | – |
| Q3 FY2017 | Sep 30, 2017 | -7251.8% | – |
| Q2 FY2017 | Jun 30, 2017 | -5555.6% | – |
| Q1 FY2017 | Mar 31, 2017 | -6333.6% | – |
See a number that looks wrong?